Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 4Gynecologic 3Head & Neck 2Genitourinary 2Dermatologic 2Thoracic 1Breast 1

Conditions

Melanoma 2

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 193aldesleukin 145Interleukin-2 109fludarabine phosphate 106Temozolomide 83Dacarbazine 81fludarabine 80Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Carboplatin 48Magnetic Resonance Spectroscopy 47Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42atezolizumab 41Specimen Handling 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Adoptive Transfer × Dermatologic × Clear all
NCT01005745 2025-12-19

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
19 enrolled 7 charts
Dermatologic

Melanoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
13 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡